Vlado Perkovic's Publications

Perkovic V, Toto R, Cooper ME et alii
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.

Journal articles
2020
Diabetes Care
Torda A, Perkovic V, Velan G
The impact of COVID-19 pandemic on medical education

Journal articles
2020
Medical Journal of Australia
Jardine MJ, Zhou Z, Mahaffey KW et alii
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial

Journal articles
2020
Journal of the American Society of Nephrology : JASN
Ohkuma T, Van Gaal L, Shaw W et alii
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

Journal articles
2020
Diabetes
Inagaki N, Yang W, Watada H et alii
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

Journal articles
2020
Diabetology International
Zhou Z, Jardine M, Li Q et alii
EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL

Conference Abstracts
2020
in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Neuen B, Mahaffey K, Cannon CP et alii
EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

Conference Abstracts
2020
in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Zhou Z, Jardine M, Heerspink H et alii
EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION

Conference Posters
2020
Chicago
Arnott C, Li J-W, Cannon CP et alii
THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL

Conference Abstracts
2020
in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Arnott C, Li Q, Kang A et alii
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Journal articles
2020
Journal of the American Heart Association
Smyth B, Chan CT, Grieve SM et alii
Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis

Journal articles
2020
Journal of Cardiac Failure
Neuen BL, Jardine MJ, Perkovic V
Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

Journal articles
2020
Nephrology
Cannon CP, Perkovic V, Agarwal R et alii
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, including Those with HbA1c <7%: Results from the CREDENCE Trial

Journal articles
2020
Circulation
Li JW, Woodward M, Perkovic V et alii
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

Journal articles
2020
JACC: Heart Failure
Neuen BL, Perkovic V
Pilot trials in nephrology: Establishing a base for large-scale randomized trials

Journal articles
2020
Journal of the American Society of Nephrology
Levey AS, Gansevoort RT, Coresh J et alii
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

Conference Papers
2020
in American Journal of Kidney Diseases
Smyth B, van den Broek-Best O, Hong D et alii
Varying association of extended hours dialysis with quality of life

Journal articles
2019
Clinical Journal of the American Society of Nephrology
Li JW, Badve SV, Zhou Z et alii
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

Journal articles
2019
The Lancet Rheumatology
Smyth B, Trongtrakul K, Haber A et alii
Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review

Journal articles
2019
BMJ Global Health
Neuen BL, Young T, Heerspink HJL et alii
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

Journal articles
2019
The Lancet Diabetes and Endocrinology
Oshima M, Jun M, Ohkuma T et alii
The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

Journal articles
2019
Diabetologia
Neuen BL, Cherney DZ, Jardine MJ et alii
Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering

Journal articles
2019
CMAJ
Zhou Z, Jardine M, Perkovic V et alii
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

Journal articles
2019
Diabetologia
Smyth B, Haber A, Trongtrakul K et alii
Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis

Journal articles
2019
JAMA Internal Medicine
Gray NA, Zuo L, Hong D et alii
Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial

Journal articles
2019
Nephrology
Perkovic V, Bain SC, Bakris G et alii
Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER

Conference Abstracts
2019
in DIABETOLOGIA

Vlado Perkovic's Publications

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.

The impact of COVID-19 pandemic on medical education

Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL

EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION

THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL

Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis

Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, including Those with HbA1c <7%: Results from the CREDENCE Trial

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

Pilot trials in nephrology: Establishing a base for large-scale randomized trials

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

Varying association of extended hours dialysis with quality of life

The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis

Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial

Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER

The George Institute for Global Health

The George Institute country sites:

Affiliation/s

Acknowledgement of Country